达格列净治疗急性心肌梗死合并应激性高血糖的效果

摘要
图/表
参考文献(17)
相关文章 (15)

全文: PDF (0 KB) HTML (33 KB)
输出: BibTeX | EndNote (RIS)

摘要

目的探讨达格列净治疗急性心肌梗死合并应激性高血糖的效果。方法选取2017年1月～2019年12月我院心内科收治的66例急性心肌梗死合并应激性高血糖患者作为研究对象，按照随机数字表法将其分为D组（30例）和I组（36例）。D组给予达格列净，I组给予胰岛素降糖。比较两组患者的血糖、心功能等指标。结果两组患者治疗1、6周后的空腹血糖（FBG）及餐后2小时血糖（2h PBG）均低于治疗前，差异有统计学意义（P<0.05）。治疗1周后，D组患者的FBG、2h PBG水平低于I组，差异有统计学意义（P<0.05）。治疗6周后，D组患者的左室射血分数（LVEF）高于I组，体重指数（BMI）低于I组，差异有统计学意义（P<0.05）。两组患者的低血糖发生率比较，差异无统计学意义（P>0.05）。结论达格列净治疗急性心肌梗死患者合并应激性高血糖的效果确切，并能够有效提升心功能，安全性良好。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：急性心肌梗死, 应激性高血糖, 达格列净

Abstract：

Objective To investigate the effect of Dapagliflozin in the treatment of acute myocardial infarction with stress hyperglycemia.Methods From January 2017 to December 2019, 66 patients with acute myocardial infarction and stress hyperglycemia who were hospitalized in the department of internal medicine cardiovascular of our hospital were selected as the research objects.They were divided into group D (30 cases) and group I (36 cases) according to the random number table method.Patients in group D were given Dapagliflozin, and group I was given Insulin.The blood glucose, cardiac function and other indicators were compared between the two groups.Results Fasting blood glucose(FBG) and blood glucose (2h PBG) at 1 and 6 weeks after treatment were both lower in the two groups than those before treatment, with statistically significant differences (P<0.05).After 1 week of treatment, the levels of FBG and 2h PBG in group D were lower than those in group I, with statistically significant differences (P<0.05).After 6 weeks of treatment, the left ventricular ejection fraction (LVEF) of group D was higher than that of group I, and the body mass index (BMI) was lower than that of group I, with statistically significant differences (P<0.05).The incidence of hypoglycemia between the two groups was not statistically significant (P>0.05).Conclusion Dapagliflozin is effective in treating patients with acute myocardial infarction combined with stress hyperglycemia, and can effectively improve cardiac function with good safety.

Key words： Acute myocardial infarction Stress hyperglycemia Dapagliflozin

作者简介: 李鹏飞（1982-），男，硕士，心内科副主任医师，研究方向：急性心肌梗死的相关危险因素干预研究

引用本文:

李鹏飞；冷飞. 达格列净治疗急性心肌梗死合并应激性高血糖的效果[J]. 中国当代医药, 2020, 27(20): 65-68.
LI Peng-fei1 LENG Fei2. Effect of Dapagliflozin in the treatment of acute myocardial infarction with stress hyperglycemia. 中国当代医药, 2020, 27(20): 65-68.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2020/V27/I20/65

[1]	Zein AF，Nasution SA，Purnamasari D，et al.The influence of hyperglycemia at admission on in-hospital arrhythmia patients with acute coronary sundrome[J].Acta Med Indones，2015，47（4）：291-296.
[2]	Terlecki M，Bednarek A，Bednarek A，et al.The risk of diabetes development in long-term observation of patients with acute hyperglycaemia during myocardial infarction[J].Kardiol Pol，2015，73（8）：606-612.
[3]	Iwakura K.Stress hyperglycemia and microvascular obstruction affter acute myocardial infarction[J].J Cardiol，2015，65（4）：270-271.
[4]	Anand SS，Dagenais GR，Mohan V，et al.Glucose levels are associated with cardiovascular disease and death in an international cohort of normal glcaemic and dysglycaemic men and women：the EpiDREAM cohort study[J].Eur J Prev Cardiol，2012，19（4）：755-764.
[5]	刘戬，潘宜智，李广镰，等.血糖对急性心肌梗死患者冠脉内介入术后近期预后的影响[J].江西医学院院报，2007，47（3）：55-58.
[6]	Van der Horst IC，Nijsten MW，Vogelzang M，et al.Persistent hyperglycemia is an independent predictor of outcome in acute myocardial infarction[J].Cardiobasc Diabetol，2007，6：2.
[7]	Worthley MI，Holmes AS，W illoughby SR，et al.The deleterious effects of hyperglycemia on platelet function in diabetic patients with acute coronary syndromes mediation by superoxide production，resolution with inetnsive insulin administration[J].J Am Coil Cardiol，2007，49（3）：304-310.
[9]	Saleem F.Dapagliflozin：cardiovascular safety and benefits in type2 diabetes mellitus[J].Cureus，2017，9（10）：e1751.
[10]	陈阳，徐兆龙，刘仁光.心肌梗死第三次全球统一定义[J].辽宁医学院学报，2013，34（1）：1-5.
[11]	娄国忠，夏志荣.急性心肌梗死与应激性高血糖关系探讨[J].心血管病防治，2004，6（4）：32-33.
[8]	Davies MJ，Dálessio DA，Fradkin J，et al.Management of hyperglycemia in type 2 diabetes，2018.A consensus report by the American Diabetes Association （ADA） and the European Association for the Study of Diabetes （EASD）[J].Diabetes Care，2018，41（12）：2669-2701.
[12]	葛均波，徐永健.内科学[M].8版.北京：人民卫生出版社，2014：733-752.
[13]	Yang W，Ji L，Zhou Z，et al.Efficacy and safety of dapagliflozin in Asian patients：A pooled analysis[J].J Diabetes，2017，9（8）：787-799.
[14]	Sha S，Polidori D，Heise T，et al.Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus[J].Diabetes Obes Metab，2014，16（11）：1087-1095.
[15]	Ferrannini G，Hach T，Crowe S，et al.Energy Balance After Sodium-Glucose Cotranspoter 2 Inhibition[J].Diabetes Care，2015，38（9）：1730-1735.
[16]	Imprialos KP，Sarafidis AI.Sodium-glucose cotransporter-2 inhibitors and blood pressure decrease：a valuable effect of a novel antidiabetic class?[J].J Hypertens，2015，33（11）：2185-2197.
[17]	Li T，Zhang Z，Kolwicz SC，et al.Defective branched-chain amino acid catabolism disrupts glucose metabolism and sensitizes the heart to ischemia-reperfusion Injury[J].Cell Metab，2017，25（2）：374-385.